West Pharmaceutical Services, Inc. (WST) Revenue by Segment

West Pharmaceutical Services revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), West Pharmaceutical Services's largest business segment was Proprietary Products, with $722.60 million or 83% of revenue, up 16.6% from a year earlier. Next: West Vantage (17%).

The fastest-growing business segment from a year earlier was Proprietary Products (+16.6%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

West Pharmaceutical Services, Inc.

WSTHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Proprietary ProductsPackaging SystemsDelivery SystemsContract Manufactured ProductsWest Vantage

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before	Trend
Proprietary Products	USD 722.60M	82.8%	+16.6%
West Vantage	USD 149.70M	17.2%	+2.0%

Sum of items USD 872.30M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Proprietary Products	722.6M	694.3M	661.8M	647.5M	619.8M	563.0M	613.9M	601.4M	559.7M	559.5M	593.7M	–	618.0M	583.1M	–	–	653.7M	601.3M	–	–	–	543.7M	–	–	–	373.5M	–	–	–	–	–	–	–	–	–	–
Packaging Systems	–	–	–	–	–	–	–	–	–	–	–	602.5M	–	–	–	567.0M	–	–	–	577.0M	587.3M	–	–	421.5M	399.5M	–	–	345.2M	360.3M	340.4M	–	325.2M	346.0M	326.2M	–	308.9M
Delivery Systems	–	–	–	–	–	–	–	–	–	–	–	144.9M	135.8M	–	–	120.0M	117.8M	–	–	129.7M	136.4M	–	–	126.6M	127.8M	–	–	111.1M	109.4M	103.1M	–	106.7M	101.5M	89.5M	–	89.3M
Contract Manufactured Products	–	–	143.2M	157.1M	–	–	134.9M	145.5M	142.4M	135.9M	138.3M	–	–	133.5M	–	–	–	118.7M	–	–	–	127.1M	–	–	–	118.1M	–	–	–	–	–	–	–	–	–	–
West Vantage	149.7M	150.6M	–	–	146.7M	135.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

West Pharmaceutical Services revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Proprietary Products	$722.6M	$694.3M	$647.5M	$619.8M	83%
West Vantage	$149.7M	$150.6M	–	$146.7M	17%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are West Pharmaceutical Services's business segments?

Proprietary Products and West Vantage (as reported for Q2 fiscal 2026).

Which business segment makes the most money for West Pharmaceutical Services?

Proprietary Products: $722.60 million, or 83% of revenue, in Q2 fiscal 2026.

MoreWest Pharmaceutical Services stock overview West Pharmaceutical Services financials West Pharmaceutical Services executive team West Pharmaceutical Services shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.